NVS is ramping up Lovenox production to supply a larger share of the US market. At the time of the product launch on July 23, NVS was able to supply 35-40% of the market, according to Craig Wheeler on today’s CC.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”